(293) Calcitonin Gene-Related Peptide Inhibitor: Role in Treatment of Hemicrania Continua, with Potential Benefit in Controlling Diarrhea

Erenumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody, approved recently for prevention of episodic and chronic migraine. CGRP is involved in the pathogenesis of migraine, and erenumab works by blocking the CGRP receptors. Common side effects include injection site reactions and constipation. Here we present a patient with hemicrania continua (HC) who responded well to erenumab, while the medication additionally treated her debilitating diarrhea. A 61-year-old female with history of intractable, refractory, chronic, daily, left hemicranial headaches with migrainous features associated with restlessness, but without cranial autonomic symptoms, was diagnosed to have HC with 100 % response to high dose indomethacin trial.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research